WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“Advanced Cell”, or the “Company”) (OTCBB: ACTC), announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million. The three investments are expected to provide proceeds sufficient to fund the Company’s general operations and working capital for the next two years. Much of the proceeds will be used to support the Company’s Retinal Pigment Epithelial (RPE) program, which the Company expects to commence later this year through the filing of an IND with the FDA, in addition to funding development of certain other pre clinical programs.
